UK Markets close in 1 hr 5 mins
  • FTSE 100

    6,347.30
    -20.28 (-0.32%)
     
  • FTSE 250

    19,385.05
    -77.66 (-0.40%)
     
  • AIM

    1,049.10
    +10.09 (+0.97%)
     
  • GBP/EUR

    1.1141
    +0.0016 (+0.15%)
     
  • GBP/USD

    1.3372
    +0.0058 (+0.4359%)
     
  • BTC-GBP

    14,711.25
    +208.56 (+1.44%)
     
  • CMC Crypto 200

    384.66
    +20.06 (+5.50%)
     
  • S&P 500

    3,619.15
    -19.20 (-0.53%)
     
  • DOW

    29,624.90
    -285.47 (-0.95%)
     
  • CRUDE OIL

    45.10
    -0.43 (-0.94%)
     
  • GOLD FUTURES

    1,778.20
    -9.90 (-0.55%)
     
  • NIKKEI 225

    26,433.62
    -211.09 (-0.79%)
     
  • HANG SENG

    26,341.49
    -553.19 (-2.06%)
     
  • DAX

    13,411.07
    +75.39 (+0.57%)
     
  • CAC 40

    5,593.29
    -4.89 (-0.09%)
     

U.S. likely to have enough COVID-19 vaccines for all vulnerable Americans by year end - official

Carl O'Donnell
·1-min read
FILE PHOTO: A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration
FILE PHOTO: A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration

By Carl O'Donnell

(Reuters) - The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday.

The U.S. government is "cautiously optimistic" that one or two vaccines, likely from Pfizer Inc or Moderna Inc, will be available by the end of the year and can begin to be distributed to Americans, officials said during a news conference.

Azar said he expects all seniors, healthcare workers, and first responders will be able to receive a vaccine as soon as January, with the rest of the American public able to get a vaccine by April.

Companies participating in the U.S. government's effort to develop a vaccine for COVID-19, dubbed Operation Warp Speed, have begun developing manufacturing capabilities even before any vaccinations have been authorized by regulators.

In an open letter published last week, Pfizer said it is unlikely to have enough data to submit for a U.S. regulatory authorization until late November, after the U.S. presidential election.

The coronavirus outbreak has been worsening in recent weeks as cold weather pushes Americans indoors, raising the chance of contracting the virus. Some 38 U.S. states and two territories have reported rising case counts. More than 8 million Americans have been infected with the novel coronavirus and more than 200,000 have died.